PAION LAUNCHES GIAPREZA(R) (ANGIOTENSIN II) FOR THE TREATMENT OF REFRACTORY HYPOTENSION IN ADULTS WITH SEPTIC OR OTHER DISTRIBUTIVE SHOCK IN GERMANY

DGAP-News: PAION AG / Key word(s): Product Launch
16.07.2021 / 11:09
The issuer is solely responsible for the content of this announcement.

PAION LAUNCHES GIAPREZA^(R) (ANGIOTENSIN II) FOR THE TREATMENT OF REFRACTORY HYPOTENSION IN ADULTS WITH SEPTIC OR OTHER DISTRIBUTIVE SHOCK IN GERMANY

- GIAPREZA^(R) is the first product launched by PAION in Europe

Aachen (Germany), 16 July 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) today announces that GIAPREZA^(R) (angiotensin II) has been launched and is now commercially available in Germany for order and delivery to customers through direct sales.

GIAPREZA^(R) is approved by the European Commission for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA^(R) is a synthetic human angiotensin II acting the same way as the body's endogenous regulatory peptide that is central to the renin-angiotensin-aldosterone system to increase blood pressure.

PAION estimates about 150,000 septic or other distributive shock patients in Europe annually remaining below target blood pressure levels despite treatment with existing therapies leading to a high mortality rate in those critically ill patients. In 2013, the mortality rate of patients in Germany with severe septic shock was as high as almost 60%^[1]. Due to this significant unmet need, PAION decided to make GIAPREZA^(R) available to patients as soon as possible and before establishing a commercial structure in Germany with other European markets to follow over the course of the next months. The initial focus of the commercial teams across Europe over the first year after launch will be to ensure that GIAPREZA^(R) is listed on hospital formularies, based on the unmet needs it can address and the health economic benefits it can deliver.

Dr. Jim Phillips, Chief Executive Officer of PAION AG, stated: "Septic and other distributive shock is a serious condition that results in increased mortality in hospitalized patients. We are excited with this first PAION product launch to bring a new treatment option to critically ill patients who contract this terrible condition."

PAION plans to launch all of its products - Byfavo^(R), GIAPREZA^(R) and XERAVA^(R) - in a staggered manner by country so that, by the end of 2022, launches will have been conducted in all selected European markets.

###

About septic or other distributive shock
Distributive shock is the most common type of shock in the inpatient setting. The inability to achieve or maintain adequate blood pressure results in inadequate blood flow to the body's organs and tissues and is associated with a mortality rate exceeding most acute conditions requiring hospitalization.

GIAPREZA^(R) (angiotensin II)
GIAPREZA^(R) for infusion is an FDA-approved vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. GIAPREZA^(R) is approved by the European Commission and the UK Medicines Agency for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA^(R) is a synthetic human angiotensin II acting the same way as the body's endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system, which in turn regulates blood pressure.

The pivotal Phase III trial of angiotensin II for the treatment of high-output shock (ATHOS-3) was a randomized, placebo-controlled, double-blind, international, multicenter Phase III safety and efficacy trial in which 321 adults with septic or other distributive shock who had hypotension despite fluid and vasopressor therapy were randomized 1:1 to GIAPREZA^(R) or placebo. The primary efficacy endpoint, an increase in blood pressure, was achieved by 70% of patients randomized to GIAPREZA^(R) compared to 23% of patients treated with placebo; p < 0.0001 (a treatment effect of 47%).

The European Summary of Product Characteristics is available on the European Medicines Agency website: www.ema.europa.eu/en/medicines/human/EPAR/giapreza

About PAION
PAION AG is a publicly listed specialty pharmaceutical with innovative drugs to be used in hospital-based sedation, anesthesia and critical care services. PAION's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic. Remimazolam is partnered in multiple territories outside of Europe. Remimazolam is approved in the U.S., the EU/EEA/UK and China for procedural sedation and in Japan and South Korea for general anesthesia.

In addition to Byfavo^(R) (remimazolam), PAION has two additional products, GIAPREZA^(R) (angiotensin II) and XERAVA^(R) (eravacycline), in its portfolio. GIAPREZA^(R) is a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies, and was launched in July 2021. XERAVA^(R) is a novel fluorocycline type of antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.

PAION's mission is to be a leading specialty pharmaceutical company in the fields of anesthesia and critical care by bringing novel products to market to benefit patients, doctors and other stakeholders in healthcare.

PAION is headquartered in Aachen (Germany).

Contact
Ralf Penner
Vice President Investor Relations/Public Relations
PAION AG
Heussstrasse 25
52078 Aachen - Germany
Phone +49 241 4453-152
E-mail r.penner@paion.com
www.paion.com

Disclaimer:
This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG' management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from PAION's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update such forward-looking statements to reflect future events or developments.

^[1] Fleischmann, C., Thomas-Rueddel, D. O., Hartmann, M., Hartog, C. S., Welte, T. et al.: Hospital Incidence and Mortality Rates of Sepsis. Dtsch Arztebl Int 2016; 113(10): 159-66.

16.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de